Intellia Therapeutics, Inc. - 8-K Filing
FDA accepted BLA with Priority Review for Lonvoguran Ziclumeran, first in vivo CRISPR-based therapy candidate for HAE (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $NTLA